Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Monfort, X. Pan, Robyn Patrick, B. Ramaswamy, R. Wesolowski, M. Naughton, C. Loprinzi, A. Chaudhari, M. Lustberg (2017)Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients
Breast Cancer Research and Treatment, 164
Lotte Wevers, G. Kwakkel, Ingrid Port (2011)Is outdoor use of the six-minute walk test with a global positioning system in stroke patients' own neighbourhoods reproducible and valid?
Journal of rehabilitation medicine, 43 11
Michael Mueller, L. Tuttle, Joseph LeMaster, M. Strube, J. McGill, M. Hastings, D. Sinacore (2013)Weight-bearing versus nonweight-bearing exercise for persons with diabetes and peripheral neuropathy: a randomized controlled trial.
Archives of physical medicine and rehabilitation, 94 5
A. Passantino, R. Lagioia, F. Mastropasqua, D. Scrutinio (2006)Short-term change in distance walked in 6 min is an indicator of outcome in patients with chronic heart failure in clinical practice.
Journal of the American College of Cardiology, 48 1
T. Postma, N. Aaronson, J. Heimans, M. Muller, J. Hildebrand, J. Delattre, K. Hoang-Xuan, M. Lanteri-Minet, R. Grant, R. Huddart, C. Moynihan, J. Maher, R. Lucey (2005)The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20.
European journal of cancer, 41 8
D. Binda, E. Vanhoutte, G. Cavaletti, D. Cornblath, T. Postma, B. Frigeni, P. Alberti, J. Bruna, R. Velasco, A. Argyriou, H. Kalofonos, D. Psimaras, D. Ricard, A. Pace, E. Galiè, C. Briani, C. Torre, R. Lalisang, W. Boogerd, D. Brandsma, S. Koeppen, J. Hense, D. Storey, S. Kerrigan, A. Schenone, S. Fabbri, E. Rossi, M. Valsecchi, C. Faber, I. Merkies, S. Galimberti, F. Lanzani, L. Mattavelli, M. Piatti, P. Bidoli, M. Cazzaniga, D. Cortinovis, M. Lucchetta, M. Campagnolo, M. Bakkers, B. Brouwer, R. Grant, L. Reni, B. Piras, A. Pessino, L. Padua, G. Granata, M. Leandri, I. Ghignotti, R. Plasmati, F. Pastorelli, J. Heimans, M. Eurelings, R. Meijer, W. Grisold, E. Pozza, A. Mazzeo, A. Toscano, M. Russo, C. Tomasello, G. Altavilla, M. Prado, C. González, S. Dorsey (2013)Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS).
European journal of cancer, 49 13
G. Vita, C. Stancanelli, L. Gentile, C. Barcellona, M. Russo, G. Bella, G. Vita, A. Mazzeo (2019)6MWT performance correlates with peripheral neuropathy but not with cardiac involvement in patients with hereditary transthyretin amyloidosis (hATTR)
Neuromuscular Disorders, 29
P. LaStayo, R. Marcus, L. Dibble, Sheldon Smith, S. Beck (2011)Eccentric exercise versus Usual-care with older cancer survivors: The impact on muscle and mobility- an exploratory pilot study
BMC Geriatrics, 11
K. Winters-Stone, F. Horak, P. Jacobs, Phoebe Trubowitz, N. Dieckmann, S. Stoyles, S. Faithfull (2017)Falls, Functioning, and Disability Among Women With Persistent Symptoms of Chemotherapy-Induced Peripheral Neuropathy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 23
D Cornblath, V Chaudhry, K Carter, D Lee, M Seysedadr, M Miernicki (1999)Total neuropathy score validation and reliability study
E. Spina, A. Topa, R. Iodice, S. Tozza, L. Ruggiero, R. Dubbioso, M. Esposito, P. Dolce, L. Santoro, F. Manganelli (2019)Six-minute walk test is reliable and sensitive in detecting response to therapy in CIDP
Journal of Neurology, 266
PL Enright (2003)The six-minute walk test
Respir Care, 48
E. Hile, G. Fitzgerald, S. Studenski (2010)Persistent Mobility Disability After Neurotoxic Chemotherapy
Physical Therapy, 90
T. Bao, Coby Basal, C. Seluzicki, Susan Li, A. Seidman, J. Mao (2016)Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk
Breast Cancer Research and Treatment, 159
Susanna Park, D. Goldstein, A. Krishnan, C. Lin, M. Friedlander, J. Cassidy, M. Koltzenburg, M. Kiernan (2013)Chemotherapy‐induced peripheral neurotoxicity: A critical analysis
CA: A Cancer Journal for Clinicians, 63
D. Hinkle, W. Wiersma, S. Jurs (1979)Applied statistics for the behavioral sciences
K. Basen-Engquist, Cindy Taylor, C. Rosenblum, Murray Smith, E. Shinn, A. Greisinger, Xylina Gregg, P. Massey, V. Valero, E. Rivera (2006)Randomized pilot test of a lifestyle physical activity intervention for breast cancer survivors.
Patient education and counseling, 64 1-3
Dawn Hamilton, R. Haennel (1999)Validity and reliability of the 6-minute walk test in a cardiac rehabilitation population.
Journal of cardiopulmonary rehabilitation, 20 3
DM Hamilton, R Haennel (2000)Validity and reliability of the 6-minute walk test in a cardiac rehabilitation population
J Cardiopulm Rehabil Prev, 20
J. Gewandter, J. Brell, G. Cavaletti, P. Dougherty, S. Evans, Lyn Howie, M. Mcdermott, A. O'Mara, A. Smith, D. Dastros-Pitei, L. Gauthier, S. Haroutounian, M. Jarpe, Nathaniel Katz, C. Loprinzi, P. Richardson, Ellen Lavoie-Smith, P. Wen, D. Turk, R. Dworkin, R. Freeman (2018)Trial designs for chemotherapy-induced peripheral neuropathy prevention
A. Ottaiano, A. Nappi, S. Tafuto, G. Nasti, C. Divitiis, C. Romano, A. Cassata, R. Casaretti, L. Silvestro, A. Avallone, Maurizio Capuozzo, M. Capozzi, P. Maiolino, V. Quagliariello, S. Scala, V. Iaffaioli (2016)Diabetes and Body Mass Index Are Associated with Neuropathy and Prognosis in Colon Cancer Patients Treated with Capecitabine and Oxaliplatin Adjuvant Chemotherapy
Bittner, D. Weiner, S. Yusuf, W. Rogers, K. Mcintyre, S. Bangdiwala, M. Kronenberg, J. Kostis, R. Kohn, M. Guillotte (1993)Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators.
JAMA, 270 14
M. Hirvensalo, T. Rantanen, E. Heikkinen (2000)Mobility Difficulties and Physical Activity as Predictors of Mortality and Loss of Independence in the Community‐Living Older Population
Journal of the American Geriatrics Society, 48
C. Cote, C. Casanova, Jose Marin, Maria Lopez, V. Pinto-Plata, M. Oca, L. Dordelly, H. Nekach, B. Celli (2008)Validation and comparison of reference equations for the 6-min walk distance test
European Respiratory Journal, 31
M. Huang, J. Blackwood, Monica Godoshian, L. Pfalzer (2017)Prevalence of self-reported falls, balance or walking problems in older cancer survivors from Surveillance, Epidemiology and End Results-Medicare Health Outcomes Survey.
Journal of geriatric oncology, 8 4
H. Yuen, D. Sword (2007)Home-based exercise to alleviate fatigue and improve functional capacity among breast cancer survivors.
Journal of allied health, 36 4
T. Sloten, H. Savelberg, Inge Duimel-Peeters, K. Meijer, R. Henry, C. Stehouwer, N. Schaper (2011)Peripheral neuropathy, decreased muscle strength and obesity are strongly associated with walking in persons with type 2 diabetes without manifest mobility limitations.
Diabetes research and clinical practice, 91 1
J. McCrary, D. Goldstein, Carolina Sandler, Carolina Sandler, Carolina Sandler, B. Barry, B. Barry, Michael Marthick, H. Timmins, Tiffany Li, L. Horvath, Lisa Horvath, P. Grimison, P. Grimison, Susanna Park, Susanna Park (2019)Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathy
Supportive Care in Cancer
T. Troosters, R. Gosselink, M. Decramer (1999)Six minute walking distance in healthy elderly subjects.
The European respiratory journal, 14 2
G. Kervio, F. Carré, N. Ville (2003)Reliability and intensity of the six-minute walk test in healthy elderly subjects.
Medicine and science in sports and exercise, 35 1
P. Alberti, E. Rossi, D. Cornblath, I. Merkies, T. Postma, B. Frigeni, J. Bruna, R. Velasco, A. Argyriou, H. Kalofonos, D. Psimaras, D. Ricard, A. Pace, E. Galiè, C. Briani, C. Torre, C. Faber, R. Lalisang, W. Boogerd, D. Brandsma, S. Koeppen, J. Hense, D. Storey, S. Kerrigan, A. Schenone, S. Fabbri, M. Valsecchi, G. Cavaletti (2014)Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin.
Annals of oncology : official journal of the European Society for Medical Oncology, 25 1
JS Gewandter, J Brell, G Cavaletti, PM Dougherty, S Evans, L Howie, MP McDermott, A O'Mara, AG Smith, D Dastros-Pitei, LR Gauthier, S Haroutounian, M Jarpe, NP Katz, C Loprinzi, P Richardson, EM Lavoie-Smith, PY Wen, DC Turk, RH Dworkin, R Freeman (2018)Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations
M. Varedi, Lu Lu, C. Howell, Robyn Partin, M. Hudson, C. Pui, K. Krull, L. Robison, K. Ness, R. McKenna (2018)Peripheral Neuropathy, Sensory Processing, and Balance in Survivors of Acute Lymphoblastic Leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36 22
F. Streckmann, F. Streckmann, H. Lehmann, M. Balke, A. Schenk, M. Oberste, A. Heller, A. Schürhörster, T. Elter, W. Bloch, F. Baumann (2018)Sensorimotor training and whole-body vibration training have the potential to reduce motor and sensory symptoms of chemotherapy-induced peripheral neuropathy—a randomized controlled pilot trial
Supportive Care in Cancer, 27
J. Gewandter, L. Fan, A. Magnuson, K. Mustian, L. Peppone, C. Heckler, J. Hopkins, M. Tejani, G. Morrow, S. Mohile (2013)Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study
Supportive Care in Cancer, 21
Julie Ries, J. Echternach, L. Nof, Michelle Blodgett (2009)Test-Retest Reliability and Minimal Detectable Change Scores for the Timed “Up & Go” Test, the Six-Minute Walk Test, and Gait Speed in People With Alzheimer Disease
Physical Therapy, 89
G. Cavaletti, B. Frigeni, F. Lanzani, M. Piatti, S. Rota, C. Briani, G. Zara, R. Plasmati, F. Pastorelli, A. Caraceni, A. Pace, M. Manicone, A. Lissoni, N. Colombo, G. Bianchi, C. Zanna (2007)The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy‐induced peripheral neurotoxicity: comparison with the National Cancer Institute‐Common Toxicity Scale
Journal of the Peripheral Nervous System, 12
E. Peters, Laura Schulz, M. Reuss-Borst (2016)Quality of life after cancer—How the extent of impairment is influenced by patient characteristics
BMC Cancer, 16
P. Zimmer, Sina Trebing, Ursula Timmers-Trebing, A. Schenk, R. Paust, W. Bloch, R. Rudolph, F. Streckmann, F. Baumann (2018)Eight-week, multimodal exercise counteracts a progress of chemotherapy-induced peripheral neuropathy and improves balance and strength in metastasized colorectal cancer patients: a randomized controlled trial
Supportive Care in Cancer, 26
C. Casanova, B. Celli, P. Barría, A. Casas, C. Cote, J. Torres, J. Jardim, M. López, J. Marin, M. Oca, V. Pinto-Plata, A. Aguirre-Jaime (2010)The 6-min walk distance in healthy subjects: reference standards from seven countries
European Respiratory Journal, 37
DL Hershman, C Lacchetti, RH Dworkin, EM Lavoie Smith, J Bleeker, G Cavaletti, C Chauhan, P Gavin, A Lavino, MB Lustberg, J Paice, B Schneider, ML Smith, T Smith, S Terstriep, N Wagner-Johnston, K Bak, CL Loprinzi (2014)Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline
J Clin Oncol, 32
V. Bittner, D. Weiner, S. Yusuf, W. Rogers, K. Mcintyre, S. Bangdiwala, M. Kronenberg, J. Kostis, R. Kohn, M. Guillotte, B. Greenberg, Patricia Woods, M. Bourassa (1993)Prediction of Mortality and Morbidity With a 6-Minute Walk Test in Patients With Left Ventricular Dysfunction
L. Olsson, K. Swedberg (2005)Six minute walk test.
European heart journal, 26 20
(2019)American Society of Clinical Oncology clinical practice guideline
Antonia Kaltsatou, Dimitra Mameletzi, S. Douka (2011)Physical and psychological benefits of a 24-week traditional dance program in breast cancer survivors.
Journal of bodywork and movement therapies, 15 2
M. Seretny, Gillian Currie, E. Sena, S. Ramnarine, R. Grant, M. Macleod, L. Colvin, M. Fallon (2014)Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis
D. Bruce, W. Davis, T. Davis (2005)Longitudinal predictors of reduced mobility and physical disability in patients with type 2 diabetes: the Fremantle Diabetes Study.
Diabetes care, 28 10
P. Enright, D. Sherrill (1998)Reference equations for the six-minute walk in healthy adults.
American journal of respiratory and critical care medicine, 158 5 Pt 1
D. Cornblath, V. Chaudhry, Kerryn Carter, D. Lee, M. Seysedadr, M. Miernicki, T. Joh (1999)Total neuropathy score
S. Lord, H. Menz (2002)Physiologic, psychologic, and health predictors of 6-minute walk performance in older people.
Archives of physical medicine and rehabilitation, 83 7
S. Wolf, D. Barton, L. Kottschade, A. Grothey, C. Loprinzi (2008)Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies.
European journal of cancer, 44 11
Nancy Harada, Nancy Harada, Nancy Harada, Vicki Chiu, Vicki Chiu, Anita Stewart (1999)Mobility-related function in older adults: assessment with a 6-minute walk test.
Archives of physical medicine and rehabilitation, 80 7
K. Schmidt, L. Vogt, C. Thiel, E. Jäger, W. Banzer (2013)Validity of the Six-Minute Walk Test in Cancer Patients
International Journal of Sports Medicine, 34
Background Chemotherapy-induced peripheral neuropathy (CIPN) is a significant and often lasting side effect of cancer treat- ment, with increasing CIPN severity associated with increasing deficits in balance, gait, and mobility. The 6-min walk test (6MWT) is a widely validated and utilized measure of general physical functioning and mobility, although its utility in a CIPN context is unclear. This study aimed to determine the utility of the 6MWT as an assessment of mobility deficits in a CIPN cohort and utilize the 6MWT to compare mobility data from CIPN patients to those of healthy and clinical populations. Methods Cancer survivors exposed to neurotoxic chemotherapies (N = 100; mean 17 ± 13 months post-treatment; mean age 59 ± 13 years) completed a single cross-sectional assessment of patient-reported and objective CIPN, mobility (6MWT), and disability. Results CIPN symptoms were reported in the majority of the cohort (87%). Increasing age, patient-reported and objective CIPN symptoms, and disability were associated with decreasing 6MWT distance (.48 ≤ R ≤ .63; p < .001) in bivariate models. Multiple regression models of 6MWT distance included age, sex, and patient-reported or objective CIPN severity as significant indepen- dent correlates (.62 ≤ R ≤ .64; p < .03). 6MWT distances
Journal of Cancer Survivorship: Research and Practice – Springer Journals
Published: Jun 6, 2019
Access the full text.
Sign up today, get DeepDyve free for 14 days.